- Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme
- Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024
- Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024
- Vedtægter for Novo Nordisk, april 2024
- Novo Nordisk A/S - Articles of Association, April 2024
- Novo Nordisk A/S – Reduction of the share capital
More ▼
Key statistics
On Monday, Novo Nordisk A/S (NOVO B:CPH) closed at 909.90, -2.37% below its 52-week high of 932.00, set on Mar 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 900.00 |
---|---|
High | 909.90 |
Low | 891.00 |
Bid | 909.90 |
Offer | 909.90 |
Previous close | 883.20 |
Average volume | 3.86m |
---|---|
Shares outstanding | 3.39bn |
Free float | 2.11bn |
P/E (TTM) | 44.33 |
Market cap | 2.99tn DKK |
EPS (TTM) | 19.91 DKK |
Annual div (ADY) | 9.40 DKK |
---|---|
Annual div yield (ADY) | 1.03% |
Div ex-date | Mar 22 2024 |
Div pay-date | Mar 26 2024 |
Data delayed at least 15 minutes, as of May 13 2024 16:10 BST.
More ▼